Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

of RA patients. By blocking the CCR1 ligands including the super-activated forms from interacting with the CCR1 receptor, CCX354 is designed to reduce the migration of inflammatory cells leading to rheumatoid arthritis and subsequently joint destruction.

"CCX354 is the third product candidate to enter the clinic from our discovery platform and marks another important milestone for ChemoCentryx," said Thomas J. Schall, Ph.D., President and Chief Executive Officer. "ChemoCentryx has repeatedly shown that it can develop clearly differentiated product candidates by leveraging its technology platform and that it can also advance them expeditiously into clinical development. In less than a year, our product pipeline has expanded from a single ongoing clinical program to now three clinical assets in development."

"We are delighted that this CCR1 antagonist program with ChemoCentryx has progressed to the clinic," said Hugh Cowley, Senior Vice President of GSK's Center of Excellence for External Drug Discovery (CEEDD). "CCX354 may become a promising drug candidate against a number of potential inflammatory diseases and we look forward to seeing the data as it emerges from the clinical trial program."

ChemoCentryx and GSK's Center of Excellence for External Drug Discovery (CEEDD) entered into a multi-product strategic alliance in August 2006 for the discovery, development and commercialization of novel medicines targeting four defined chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders. Under the terms of the agreement, ChemoCentryx is responsible for the discovery and development of up to six small molecule drug candidates across four targets through clinical proof-of-concept, at which point GSK will have exclusive options to license each product for further development and commercialization on a worldwide basis. CCX354 is the second compound under the GSK alliance to enter the clinic. ChemoCentryx's lead com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 2011 , ReportsnReports adds market ... & Forecasts to 2017 for Greece, Hungary & ... provide value (USD million), volume (units) and average ... within 10 market categories - Cardiac Assist Devices, ...
... Mass., Sept. 20, 2011 Intrinsic Therapeutics, a ... address the spine market,s many unmet needs, today ... and Chief Executive Officer. Mr. Hagan brings over ... field with significant expertise in product development, commercialization ...
Cached Medicine Technology:ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 2ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 3ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 4Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO 2
(Date:7/10/2014)... health-conscious people around the globe have taken antioxidant supplements ... one of the paths to good health and a ... antioxidant supplements have repeatedly dashed the hopes of consumers ... Virtually all such trials have failed to show ... several trials antioxidant supplementation has been linked with increased ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... reveal that sudden, acute episodes of low back pain ... humidity, air pressure, wind direction and precipitation. Findings published ... of the American College of Rheumatology (ACR), indicate that ... higher wind speed or wind gusts, but was not ... Organization (WHO) nearly everyone experiences low back pain at ...
(Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... price of efavirenz 600mg tablets (Stocrin) for developing countries that ... ,It is the second price cut in a ... efavirenz cheaper than a generic import in Thailand, where a ... from India. ,For least developed countries and ...
... case management that takes a patient’s specific culture ... decrease the incidence of diabetes-related complications over the ... ,"Better management results in reduced long-term complications, such ... lead researcher Todd Gilmer, Ph.D. ,The ...
... Japanese researchers have successfully developed artificial teeth that they ... eventually help with similar procedures in humans. ... a single cell implanted into the mouths of adult ... in humans, reported the online edition of Australia's The ...
... Insufficient sleep at night could have an adverse effect ... that shows// how important the evening slumber is for ... University Of Colorado School Of Medicine and other researchers ... out by students attending middle school or high school, ...
... not worry about getting their bodies back into shape immediately, ... body has enough to do after a baby arrives," said ... ,New mothers also have to reckon with fatigue ... Pfarrer of the insurer DAK in Hamburg. And nursing a ...
... have literally found the needle in the haystack as ... help to discover hitherto unknown genetic material that causes ... in the prevention and treatment of autism has been ... all part of an international team from 8 countries ...
Cached Medicine News:Health News:Culturally Specific Diabetes Management Helps Low-Income Patients 2Health News:Sleep Disturbances Could Affect Performances in School 2Health News:New Gene Linked to Autism Discovered 2
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urine Chemistry Control is a liquid product ideal for monitoring urine chemistry testing procedures. It provides assayed values for urine tests commonly performed on chemistry analyzers and...
Medicine Products: